Population pharmacokinetic and exposure–response analysis for trastuzumab administered using a subcutaneous “manual syringe” injection or intravenously in women with HER2-positive early breast cancer
Crossref DOI link: https://doi.org/10.1007/s00280-015-2922-5
Published Online: 2015-12-08
Published Print: 2016-01
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Quartino, Angelica L.
Hillenbach, Carina
Li, Jing
Li, Hanbin
Wada, Russell D.
Visich, Jennifer
Li, Chunze
Heinzmann, Dominik
Jin, Jin Y.
Lum, Bert L.
Funding for this research was provided by:
F. Hoffmann-La Roche Ltd
Genentech, Inc.
License valid from 2015-12-08